相关实验视频

Updated: Jan 6, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

含有Pyrazole-Pyridine混合物作为新型抗癌剂的库尔库明类型:合成,细胞毒性,亡诱导和分子建模

Nam Q H Doan¹, Huyen T T Nguyen¹, Hoang-Thuc Huynh¹

¹School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, 41 Dinh Tien Hoang Street, Sai Gon Ward, Ho Chi Minh City, 70000, Vietnam.

|September 14, 2025

概括

新的黄素类似物与Pyrazole-pyridine杂交物显示出强大的抗癌活性. 化合物4c表现出显著的细胞毒性和亡诱导,比原始化合物具有更好的性能.

科学领域:

药用化学医学化学
有机合成有机合成
癌症研究癌症研究

背景情况:

黄素类似物是有前途的抗癌剂,但存在局限性.
之前的研究集中在与1H-pyrazole融合的黄素类似物上.
结构修改是提高抗癌疗效的关键.

研究的目的:

开发新型的黄素类似物与皮拉-皮里丁杂交物.
为了研究这些新化合物的抗癌潜力.
评估生物异构替代物对化合物特性的影响.

主要方法:

使用生物异构替代物 (烯与胺) 替代库尔库明类型的结构修改.
合成Pyrazole-pyridine混合库尔库明类型 (化合物3a-4h) 的合成.
在体外细胞毒性测定对HepG2,MDA-MB-231和A549癌细胞系.
在HepG2细胞中进行亡诱导研究.
在物理化学 - 药理动力学 - 毒理学概况和素结合的in silico预测.

主要成果:

化合物4c对肝,乳腺和肺癌细胞系表现出最高的细胞毒性.
化合物4c在HepG2细胞中诱导显著的亡.
化合物4c表现出有利的预测物理化学-药物动力学-毒理学特性.
化合物4c在α,β-tubulin的菌素结合部位表现出有效的结合.
化合物4c中的生物异构替代物改善了抗癌活性和特性.

结论:

新型的pyrazole-pyridine混合库尔库明类型是有效的抗癌剂.
化合物4c是一种强大的化合物,具有增强的抗癌活性和有利的特性.
生物异构体替代策略有利于开发改进的黄素类似物.

关键词:

灭症 (apoptosis) 是一种死亡的过程.科尔奇辛-结合部位库尔库明类似的库尔库明.细胞毒性细胞毒性皮拉 (pyrazole) 是一种可怕的药物.氨酸是什么?氨酸是什么?管道中的管道.

更多相关视频

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...